APA

Lerario A. M., Worden F. P., Ramm C. A., Hesseltine E. A., Hasseltine E. A., Stadler W. M., Else T., Shah M. H., Agamah E., Rao K. & Hammer G. D. (20150408). The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. : Hormones & cancer.

Chicago

Lerario Antonio M, Worden Francis P, Ramm Carole A, Hesseltine Elizabeth A, Hasseltine Elizabeth A, Stadler Walter M, Else Tobias, Shah Manisha H, Agamah Edem, Rao Krishna and Hammer Gary D. 20150408. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. : Hormones & cancer.

Harvard

Lerario A. M., Worden F. P., Ramm C. A., Hesseltine E. A., Hasseltine E. A., Stadler W. M., Else T., Shah M. H., Agamah E., Rao K. and Hammer G. D. (20150408). The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. : Hormones & cancer.

MLA

Lerario Antonio M, Worden Francis P, Ramm Carole A, Hesseltine Elizabeth A, Hasseltine Elizabeth A, Stadler Walter M, Else Tobias, Shah Manisha H, Agamah Edem, Rao Krishna and Hammer Gary D. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. : Hormones & cancer. 20150408.